Mercy BioAnalytics

About Mercy BioAnalytics

Mercy BioAnalytics is dedicated to early cancer detection to save lives. They focus on developing highly accurate, low-cost, and accessible blood-based tests using their proprietary Mercy Halo™ platform to detect cancer at its earliest, most curable stages.

Products & Services

Mercy Halo™ Platform:A patented platform using low-cost qPCR technology and extracellular vesicles (EVs) to develop sensitive and specific blood-based tests for early cancer detection.

Specialties

Early Cancer Detection Extracellular Vesicles (EVs) Blood-Based Testing qPCR Technology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 59000000 MR: - FA: $59 million FAN: 59000000	D: 2025-09-03 FD: 2025-09-03	11 investors
2	RT: Series A T: - FT: Series A	A: 41000000 MR: - FA: $41 million FAN: 41000000	D: 2023-04-03 FD: 2023-04-03	9 investors

Series B Latest

2025-09-03

$59.0M

11 investors (Pro only)

Series A 2023-04-03

$41.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dawn Mattoon

Chief Executive Officer

D

Diane Marcou

Chief Financial Officer

T

Toumy Guettouche

Chief Scientific Officer

J

Josh Gralapp

Vice President, Commercial

M

Michael Smith

Senior Vice President, Operations

T

Tim Membrino

Vice President of Program & Portfolio Management

View 15 more team members with Pro

Unlock Full Team Directory

Recent News